Good News | Hycells Awarded the Title of “Shanghai Specialized, Refined, Distinctive, and Innovative SME” for 2024
Release Date:
2024-09-18 14:32
On September 6, 2024, the Shanghai Municipal Commission of Economy and Informatization issued the “ List of Specialized, Sophisticated, and Novel Small and Medium-Sized Enterprises in Shanghai for 2024 (Second Batch) The public list has been released, and Shanghai Hycells Biotechnology Co., Ltd. is honored to be included.
Officially and authoritatively confirmed once again
Following He Shengyou's acquisition Shanghai High-Tech Enterprise Certification, once again honored as “ Shanghai Municipal Specialized, Sophisticated, and Novel Small and Medium-Sized Enterprises “It is recognized that this honor represents a high level of affirmation of Hycells’s corporate development philosophy, further strengthening Hycells’s commitment to…” Quality First ， Innovation-Driven This has laid a solid foundation for Hycells to attract more high-caliber talent and resources and to expand its market footprint, while also aligning with the company’s core values-driven development strategy and strategic positioning.
Public Notice on the Official Website of the Shanghai Municipal Commission of Economy and Informatization
List of Publicly Announced Enterprises
Quality First, Innovation-Based
“Specialized, Refined, Distinctive, and Innovative” enterprises are those that possess “ Professionalization, refinement, specialization, and innovation “characterized by small and medium-sized enterprises. Hycells has fully articulated this philosophy: by deeply cultivating the niche segment of primary cells, the company achieves refined and differentiated product technologies in the primary-cell space, delivering specialized products and services that meet market needs. The company has continuously increased its R&D investment and built a high-caliber R&D team, which has played a crucial role in Hycells’s upgrade and transformation.”
Hycells has always put into practice “ Quality First, Innovation as the Foundation Its core values are to truly empower customers and address the pain points and challenges they face in the field of innovative drug R&D. Beyond focusing on its own development, Hycells is also actively engaged in the upgrading and transformation of the entire industry. Through technology transfer and collaborative R&D initiatives, the company works closely with upstream and downstream players across the value chain to jointly promote the high-quality development of the biopharmaceutical industry.
Hycells will continue to deepen its investment in research and development, optimize its product portfolio, and enhance service quality. In the face of a future that presents both opportunities and challenges, Hycells will Stay true to our original aspiration and forge ahead with determination!
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board